Back to Search
BERNHARD ORTEL, MD
MD
Dermatology Physician
NPI: 1245405497IndividualAccepts Medicare
Education
OTHER
Class of 1982
Research & Publications (14)
Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells.
PMID 16868543·Br J Cancer·2006
8-other
Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells.
PMID 16820882·Int J Oncol·2006
7-preclinical
Targeted optical imaging and photodynamic therapy.
PMID 15524219·Ernst Schering Res Found Workshop·2005
6-review
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.
PMID 12518325·Prostate·2003
7-preclinical
Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells.
PMID 12439724·Br J Cancer·2002
8-other
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.
PMID 11960381·Oncogene·2002
7-preclinical
Detection of female lower genital tract dysplasia using orally administered 5-aminolevulinic acid induced protoporphyrin IX: a preliminary study.
PMID 11925131·Gynecol Oncol·2002
3-trial
PUVA downregulates whn expression in primary mouse keratinocytes.
PMID 11705733·J Photochem Photobiol B·2001
7-preclinical
Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer.
PMID 11585749·Cancer Res·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 5841 SOUTH MARYLAND AVENUE, MC5067
CHICAGO, IL 60637 - Phone
- (773) 702-6559
Quick Facts
- NPI
- 1245405497
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 44
- Publications
- 14
Are you this provider?
Claim Your Profile